-
Sector Analysis
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the epilepsy market through 2035. GlobalData anticipates that the global adult epilepsy market will grow steadily during the forecast period, with 7MM sales expected to increase from $11.4 billion in 2025 to $17.8 billion in 2035, at a compound annual growth rate (CAGR) of 4.5%. In 2025, the US contributed approximately $9.2 billion in drug sales, representing 80.4% of the total adult epilepsy market across the...
-
Sector Analysis
Epilepsy: Epidemiology Report and Forecast to 2035
Epilepsy is a neurological condition defined by repeated, unpredictable seizures resulting from abrupt, chaotic, and intense electrical activity among brain cells (World Health Organization, 2024a). Globally, it ranks as one of the most widespread neurological disorders (World Health Organization, 2024a). This chronic condition can develop at any point in a person's life. A diagnosis typically occurs after an individual experiences at least one seizure and sees a specialist, who evaluates detailed accounts of both the pre-seizure warning signs and the...
-
Product Insights
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2026" provides an overview of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Clinical trials scenario. This report provides top line data relating to the clinical trials on Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Epilepsy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Epilepsy - Global Clinical Trials Review, 2025" provides an overview of Epilepsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Lennox-Gastaut Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Lennox-Gastaut Syndrome- Global Clinical Trials Review, 2025" provides an overview of Lennox-Gastaut Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Lennox-Gastaut Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Seizures - Drugs In Development, 2024
Empower your strategies with our Seizures – Drugs In Development, 2024 report and make more profitable business decisions. A seizure is a medical condition where the patient has a temporary, unstoppable surge of electrical brain activity. Affected brain cells uncontrollably fire signals to others around them, overloading the affected areas of the brain. That overload can cause a wide range of symptoms or effects, including abnormal sensations, passing out, and uncontrolled muscle movements. Up to 11% of people in the US...
-
Product Insights
Childhood Epilepsy - Drugs In Development, 2024
Empower your strategies with our Childhood Epilepsy – Drugs In Development, 2024 report and make more profitable business decisions. Childhood epilepsy is a neurological disorder characterized by recurring seizures in children. Seizures result from abnormal electrical activity in the brain, causing temporary disruptions in behavior, awareness, sensation, or consciousness. This condition can manifest in various forms, from brief staring spells to convulsions or loss of consciousness. The causes of childhood epilepsy can vary, including genetic factors, brain injury, infections, developmental disorders,...
-
Product Insights
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Drugs In Development, 2024
Empower your strategies with our Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Drugs In Development, 2024 report and make more profitable business decisions. Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare genetic disorder that causes a severe form of epilepsy. It usually starts in the first year of life with prolonged seizures triggered by fever or high temperature. Children with Dravet syndrome have various types of seizures that are difficult to treat with medications. They...
-
Product Insights
Lennox-Gastaut Syndrome - Drugs In Development, 2024
Empower your strategies with our Lennox-Gastaut Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that starts in early childhood, usually before the age of 4 years. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and abnormal brain electric activity. The seizures are frequent, occurring daily, and difficult to treat with anti-seizure medications. The most common seizure type is tonic seizure, which causes sudden stiffening...
-
Product Insights
Epileptic Encephalopathy - Drugs In Development, 2024
Empower your strategies with our Epileptic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Epileptic encephalopathies, characterized by epileptiform abnormalities and progressive cerebral dysfunction, present in eight age-related syndromes as per the International League Against Epilepsy. Neonatal syndromes include early myoclonic encephalopathy and Ohtahara syndrome, while infancy sees West syndrome and Dravet syndrome. Childhood and adolescence encompass myoclonic status, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, and epilepsy with continuous spike waves during slow wave sleep. Diagnosis entails EEG...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.